Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Novo Nordisk Profits Soar in 2024 Mid-Year Report

Aug 7, 2024

On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024.  Novo Nordisk’s total sales equalled DKK 133.4 billion in the first six months of 2024, an increase of 24% in DKK and 25% when measured according to constant exchange rates (CER).

Diabetes and Obesity care sales saw an increase of 27% (CER) to DKK 125 billion (US$18.3bn), primarily driven by GLP-1 diabetes sales growth of 32% (CER) and Obesity care, including products such as Ozempic, growing by 37% (CER).  Novo Nordisk reports that it continues to be the global market leader in the GLP-1 segment for diabetes care with 56% value market share.

Highlights for the first 6 months of 2024 are reported to include the approval of Awiqli® (insulin icodec) in the EU (March 2024), Japan and China (June 2024) and a label extension for Wegovy® (semaglutide) in the EU (July 2024).

The second half of 2024 is expected to see a further 22-28% (CER) growth in sales and operating profit is expected to grow by as much as 20-28% (CER).